1366 related articles for article (PubMed ID: 32275969)
1. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
3. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
4. Using mouse liver cancer models based on somatic genome editing to predict immune checkpoint inhibitor responses.
Yuen VW; Chiu DK; Law CT; Cheu JW; Chan CY; Wong BP; Goh CC; Zhang MS; Xue HD; Tse AP; Zhang Y; Lau HY; Lee D; Au-Yeung RKH; Wong CM; Wong CC
J Hepatol; 2023 Feb; 78(2):376-389. PubMed ID: 36455783
[TBL] [Abstract][Full Text] [Related]
5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
6. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 therapy reverses TIGIT
Wang J; Yang L; Wang HX; Cui SP; Gao Y; Hu B; Zhou L; Lang R
Int Immunopharmacol; 2024 Mar; 130():111681. PubMed ID: 38368771
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
9. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
[TBL] [Abstract][Full Text] [Related]
10. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
[TBL] [Abstract][Full Text] [Related]
12. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
13. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
14. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
15. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
16. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
17. ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Wang F; Hou W; Chitsike L; Xu Y; Bettler C; Perera A; Bank T; Cotler SJ; Dhanarajan A; Denning MF; Ding X; Breslin P; Qiang W; Li J; Koleske AJ; Qiu W
Gastroenterology; 2020 Jul; 159(1):289-305.e16. PubMed ID: 32171747
[TBL] [Abstract][Full Text] [Related]
18. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Torrens L; Montironi C; Puigvehí M; Mesropian A; Leslie J; Haber PK; Maeda M; Balaseviciute U; Willoughby CE; Abril-Fornaguera J; Piqué-Gili M; Torres-Martín M; Peix J; Geh D; Ramon-Gil E; Saberi B; Friedman SL; Mann DA; Sia D; Llovet JM
Hepatology; 2021 Nov; 74(5):2652-2669. PubMed ID: 34157147
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis.
Huang XY; Zhang PF; Wei CY; Peng R; Lu JC; Gao C; Cai JB; Yang X; Fan J; Ke AW; Zhou J; Shi GM
Mol Cancer; 2020 May; 19(1):92. PubMed ID: 32430013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
